Preliminary data suggest that pts with pulmonary arterial hypertension (PAH) at intermediate risk on phosphodiesterase-5 inhibitors (PDE5i)-based therapy may benefit from switching to riociguat (RIO), a soluble guanylate cyclase stimulator. Here we compare switching to RIO vs continued PDE5i in intermediate-risk PAH pts not at treatment goal, including prespecified subgroups in the open-label, Phase 4 REPLACE study (NCT02891850). METHODS: Intermediate-risk PAH pts (WHO functional class [FC] III, 6-minute walk distance [6MWD] 165-440 m) on stable doses of PDE5i þ/endothelin receptor antagonist (ERA) were randomized to continue PDE5i or receive RIO up to 2.5 mg tid for 24 weeks. ERAs were continued in both arms. The blinded, centrally adjudicated composite primary endpoint was defined as no clinical worsening (CW) (death from any cause, hospitalization for worsening PAH, or disease progression) plus clinical improvement
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.